Dietary Quercetin and other Polyphenols: Attenuation of Obesity

Polyphenols in Human Health and Disease

Volumn 1, Issue , 2013, Pages 163-175

  Kobori, Masuko ^a  

^a NATIONAL FOOD RESEARCH INSTITUTE   (Japan)

Author keywords

Catechin; Curcumin; Inflammation; Metabolic syndrome; Oxidative stress; Quercetin; Resveratrol

Indexed keywords

EID: 84902570382     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-398456-2.00014-1     Document Type: Chapter

References (130)

1. Despres J.P., Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006, 444(7121):881-887.
2. Swinburn B.A., Sacks G., Hall K.D., Mc Pherson K., Finegood D.T., Moodie M.L., et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet 2011, 378(9793):804-814.
3. Friedman J.M. Obesity: causes and control of excess body fat. Nature 2009, 459(7245):340-342.
4. Pereira M.A., Kottke T.E., Jordan C., O'Connor P.J., Pronk N.P., Carreon R. Preventing and managing cardiometabolic risk: the logic for intervention. Int J Environ Res Public Health 2009, 6(10):2568-2584.
5. van Dam R.M., Rimm E.B., Willett W.C., Stampfer M.J., Hu F.B. Dietary patterns and risk for type-2 diabetes mellitus in U.S. men. Ann Intern Med 2002, 136(3):201-209.
6. Heidemann C., Schulze M.B., Franco O.H., van Dam R.M., Mantzoros C.S., Hu F.B. Dietary patterns and risk of mortality from cardiovascular disease, cancer, and all causes in a prospective cohort of women. Circulation 2008, 118(3):230-237.
7. Boden-Albala B., Elkind M.S., White H., Szumski A., Paik M.C., Sacco R.L. Dietary total fat intake and ischemic stroke risk: the Northern Manhattan Study. Neuroepidemiology 2009, 32(4):296-301.
8. Buettner R., Scholmerich J., Bollheimer L.C. High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity (Silver Spring) 2007, 15(4):798-808.
9. van Baak M.A., Astrup A. Consumption of sugars and body weight. Obes Rev 2009, 10(Suppl. 1):9-23.
10. Te Morenga L., Mallard S., Mann J. Dietary sugars and body weight: systematic review and meta-analyses of randomised controlled trials and cohort studies. BMJ 2012, 346:e7492.
11. Bray G.A., Nielsen S.J., Popkin B.M. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr 2004, 79(4):537-543.
12. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114(12):1752-1761.
13. Dandona P., Aljada A., Chaudhuri A., Mohanty P., Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005, 111(11):1448-1454.
14. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444(7121):860-867.
15. Bondia-Pons I., Ryan L., Martinez J.A. Oxidative stress and inflammation interactions in human obesity. J Physiol Biochem 2012, 68(4):701-711.
16. Esposito K., Ciotola M., Giugliano D. Mediterranean diet and the metabolic syndrome. Mol Nutr Food Res 2007, 51(10):1268-1274.
17. Buckland G., Bach A., Serra-Majem L. Obesity and the Mediterranean diet: a systematic review of observational and intervention studies. Obes Rev 2008, 9(6):582-593.
18. Serra-Majem L., Roman B., Estruch R. Scientific evidence of interventions using the Mediterranean diet: a systematic review. Nutr Rev 2006, 64(2 Pt 2):S27-S47.
19. Boeing H., Bechthold A., Bub A., Ellinger S., Haller D., Kroke A., et al. Critical review: vegetables and fruit in the prevention of chronic diseases. Eur J Nutr 2012, 51(6):637-663.
20. Mink P.J., Scrafford C.G., Barraj L.M., Harnack L., Hong C.P., Nettleton J.A., et al. Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women. Am J Clin Nutr 2007, 85(3):895-909.
21. Arts I.C., Hollman P.C. Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr 2005, 81(1 Suppl):317S-325S.
22. Grassi D., Aggio A., Onori L., Croce G., Tiberti S., Ferri C., et al. Tea, flavonoids, and nitric oxide-mediated vascular reactivity. J Nutr 2008, 138(8):1554S-1560S.
23. Stangl V., Lorenz M., Stangl K. The role of tea and tea flavonoids in cardiovascular health. Mol Nutr Food Res 2006, 50(2):218-228.
24. Thielecke F., Boschmann M. The potential role of green tea catechins in the prevention of the metabolic syndrome - a review. Phytochemistry 2009, 70(1):11-24.
25. Deka A., Vita J.A. Tea and cardiovascular disease. Pharmacol Res 2011, 64(2):136-145.
26. Wolfram S., Wang Y., Thielecke F. Anti-obesity effects of green tea: from bedside to bench. Mol Nutr Food Res 2006, 50(2):176-187.
27. Thavanesan N. The putative effects of green tea on body fat: an evaluation of the evidence and a review of the potential mechanisms. Br J Nutr 2011, 106(9):1297-1309.
28. Phung O.J., Baker W.L., Matthews L.J., Lanosa M., Thorne A., Coleman C.I. Effect of green tea catechins with or without caffeine on anthropometric measures: a systematic review and meta-analysis. Am J Clin Nutr 2010, 91(1):73-81.
29. Hursel R., Viechtbauer W., Westerterp-Plantenga M.S. The effects of green tea on weight loss and weight maintenance: a meta-analysis. Int J Obes (Lond) 2009, 33(9):956-961.
30. Westerterp-Plantenga M.S. Green tea catechins, caffeine and body-weight regulation. Physiol Behav 2010, 100(1):42-46.
31. Lu C., Zhu W., Shen C.L., Gao W. Green tea polyphenols reduce body weight in rats by modulating obesity-related genes. PLoS One 2012, 7(6):e38332.
32. Sae-tan S., Grove K.A., Lambert J.D. Weight control and prevention of metabolic syndrome by green tea. Pharmacol Res 2011, 64(2):146-154.
33. Chen Y.K., Cheung C., Reuhl K.R., Liu A.B., Lee M.J., Lu Y.P., et al. Effects of green tea polyphenol (-)-epigallocatechin-3-gallate on newly developed high-fat/Western-style diet-induced obesity and metabolic syndrome in mice. J Agric Food Chem 2011, 59(21):11862-11871.
34. Perez-Jimenez J., Neveu V., Vos F., Scalbert A. Systematic analysis of the content of 502 polyphenols in 452 foods and beverages: an application of the phenol-explorer database. J Agric Food Chem 2010, 58(8):4959-4969.
35. Prior R.L. Fruits and vegetables in the prevention of cellular oxidative damage. Am J Clin Nutr 2003, 78(3 Suppl):570S-578S.
36. Arai Y., Watanabe S., Kimira M., Shimoi K., Mochizuki R., Kinae N. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J Nutr 2000, 130(9):2243-2250.
37. Hollman P.C., Cassidy A., Comte B., Heinonen M., Richelle M., Richling E., et al. The biological relevance of direct antioxidant effects of polyphenols for cardiovascular health in humans is not established. J Nutr 2011, 141(5):989S-1009S.
38. Russo G.L. Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem Pharmacol 2007, 74(4):533-544.
39. Peterson J.J., Dwyer J.T., Jacques P.F., Mc Cullough M.L. Associations between flavonoids and cardiovascular disease incidence or mortality in European and US populations. Nutr Rev 2012, 70(9):491-508.
40. Knekt P., Kumpulainen J., Jarvinen R., Rissanen H., Heliovaara M., Reunanen A., et al. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr 2002, 76(3):560-568.
41. Mennen L.I., Sapinho D., de Bree A., Arnault N., Bertrais S., Galan P., et al. Consumption of foods rich in flavonoids is related to a decreased cardiovascular risk in apparently healthy French women. J Nutr 2004, 134(4):923-926.
42. Chun O.K., Chung S.J., Claycombe K.J., Song W.O. Serum C-reactive protein concentrations are inversely associated with dietary flavonoid intake in U.S. adults. J Nutr 2008, 138(4):753-760.
43. Day A.J., Mellon F., Barron D., Sarrazin G., Morgan M.R., Williamson G. Human metabolism of dietary flavonoids: identification of plasma metabolites of quercetin. Free Radic Res 2001, 35(6):941-952.
44. Graf B.A., Ameho C., Dolnikowski G.G., Milbury P.E., Chen C.Y., Blumberg J.B. Rat gastrointestinal tissues metabolize quercetin. J Nutr 2006, 136(1):39-44.
45. Murota K., Terao J. Antioxidative flavonoid quercetin: implication of its intestinal absorption and metabolism. Arch Biochem Biophys 2003, 417(1):12-17.
46. Kobori M., Masumoto S., Akimoto Y., Oike H. Chronic dietary intake of quercetin alleviates hepatic fat accumulation associated with consumption of a Western-style diet in C57/BL6J mice. Mol Nutr Food Res 2011, 55(4):530-540.
47. Inoue M., Ohtake T., Motomura W., Takahashi N., Hosoki Y., Miyoshi S., et al. Increased expression of PPARγ in high fat diet-induced liver steatosis in mice. Biochem Biophys Res Commun 2005, 336(1):215-222.
48. Sekiya M., Hiraishi A., Touyama M., Sakamoto K. Oxidative stress induced lipid accumulation via SREBP1c activation in HepG2 cells. Biochem Biophys Res Commun 2008, 375(4):602-607.
49. Kumashiro N., Tamura Y., Uchida T., Ogihara T., Fujitani Y., Hirose T., et al. Impact of oxidative stress and peroxisome proliferator-activated receptor γ coactivator-1α in hepatic insulin resistance. Diabetes 2008, 57(8):2083-2091.
50. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005, 26(3):439-451.
51. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116(7):1784-1792.
52. Kersten S., Desvergne B., Wahli W. Roles of PPARs in health and disease. Nature 2000, 405(6785):421-424.
53. Houstis N., Rosen E.D., Lander E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006, 440(7086):944-948.
54. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factorα: direct role in obesity-linked insulin resistance. Science 1993, 259(5091):87-91.
55. Shibasaki M., Takahashi K., Itou T., Miyazawa S., Ito M., Kobayashi J., et al. Alterations of insulin sensitivity by the implantation of 3T3-L1 cells in nude mice. A role for TNF-alpha?. Diabetologia 2002, 45(4):518-526.
56. Jung C.H., Cho I., Ahn J., Jeon T.I., Ha T.Y. Quercetin reduces high-fat diet-induced fat accumulation in the liver by regulating lipid metabolism genes. Phytother Res 2013, 27(1):139-143.
57. Stewart L.K., Wang Z., Ribnicky D., Soileau J.L., Cefalu W.T., Gettys T.W. Failure of dietary quercetin to alter the temporal progression of insulin resistance among tissues of C57BL/6J mice during the development of diet-induced obesity. Diabetologia 2009, 52(3):514-523.
58. Stewart L.K., Soileau J.L., Ribnicky D., Wang Z.Q., Raskin I., Poulev A., et al. Quercetin transiently increases energy expenditure but persistently decreases circulating markers of inflammation in C57BL/6J mice fed a high-fat diet. Metabolism 2008, 57(7 Suppl. 1):S39-S46.
59. Rivera L., Moron R., Sanchez M., Zarzuelo A., Galisteo M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity (Silver Spring) 2008, 16(9):2081-2087.
60. Panchal S.K., Poudyal H., Brown L. Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats. J Nutr 2012, 142(6):1026-1032.
61. Hoek-van Den Hil E.F., Keijer J., Bunschoten A., Vervoort J.J., Stankova B., Bekkenkamp M., et al. Quercetin induces hepatic lipid omega-oxidation and lowers serum lipid levels in mice. PLoS One 2013, 8(1):e51588.
62. Egert S., Wolffram S., Bosy-Westphal A., Boesch-Saadatmandi C., Wagner A.E., Frank J., et al. Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J Nutr 2008, 138(9):1615-1621.
63. Egert S., Rimbach G., Muller M.J. No evidence for a thermic effect of the dietary flavonol quercetin: a pilot study in healthy normal-weight women. Eur J Appl Physiol 2011, 111(5):869-873.
64. Rao Y.K., Geethangili M., Fang S.H., Tzeng Y.M. Antioxidant and cytotoxic activities of naturally occurring phenolic and related compounds: a comparative study. Food Chem Toxicol 2007, 45(9):1770-1776.
65. Terao J. Dietary flavonoids as antioxidants. Forum Nutr 2009, 61:87-94.
66. Meyers K.J., Rudolf J.L., Mitchell A.E. Influence of dietary quercetin on glutathione redox status in mice. J Agric Food Chem 2008, 56(3):830-836.
67. Dufour C., Loonis M. Flavonoids and their oxidation products protect efficiently albumin-bound linoleic acid in a model of plasma oxidation. Biochim Biophys Acta 2007, 1770(6):958-965.
68. Morales J., Gunther G., Zanocco A.L., Lemp E. Singlet oxygen reactions with flavonoids. A theoretical-experimental study. PLoS One 2012, 7(7):e40548.
69. Lagoa R., Graziani I., Lopez-Sanchez C., Garcia-Martinez V., Gutierrez-Merino C. Complex I and cytochrome c are molecular targets of flavonoids that inhibit hydrogen peroxide production by mitochondria. Biochim Biophys Acta 2011, 1807(12):1562-1572.
70. Mahesh T., Menon V.P. Quercetin allievates oxidative stress in streptozotocin-induced diabetic rats. Acta Phytother Res 2004, 18(2):123-127.
71. Morgan M.J., Liu Z.G. Crosstalk of reactive oxygen species and NFκB signaling. Cell Res 2011, 21(1):103-115.
72. Thannickal V.J., Fanburg B.L. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 2000, 279(6):L1005-L1028.
73. Boesch-Saadatmandi C., Wagner A.E., Wolffram S., Rimbach G. Effect of quercetin on inflammatory gene expression in mice liver in vivo - role of redox factor 1, miRNA-122 and miRNA-125b. Pharmacol Res 2012, 65(5):523-530.
74. Morand C., Crespy V., Manach C., Besson C., Demigne C., Remesy C. Plasma metabolites of quercetin and their antioxidant properties. Am J Physiol 1998, 275(1 Pt 2):R212-R219.
75. Manach C., Morand C., Crespy V., Demigne C., Texier O., Regerat F., et al. Quercetin is recovered in human plasma as conjugated derivatives which retain antioxidant properties. FEBS Lett 1998, 426(3):331-336.
76. Shanely R.A., Knab A.M., Nieman D.C., Jin F., Mc Anulty S.R., Landram M.J. Quercetin supplementation does not alter antioxidant status in humans. Free Radic Res 2010, 44(2):224-231.
77. Egert S., Bosy-Westphal A., Seiberl J., Kurbitz C., Settler U., Plachta-Danielzik S., et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br J Nutr 2009, 102(7):1065-1074.
78. Edwards R.L., Lyon T., Litwin S.E., Rabovsky A., Symons J.D., Jalili T. Quercetin reduces blood pressure in hypertensive subjects. J Nutr 2007, 137(11):2405-2411.
79. Lee K.H., Park E., Lee H.J., Kim M.O., Cha Y.J., Kim J.M., et al. Effects of daily quercetin-rich supplementation on cardiometabolic risks in male smokers. Nutr Res Pract 2011, 5(1):28-33.
80. Kobori M., Masumoto S., Akimoto Y., Takahashi Y. Dietary quercetin alleviates diabetic symptoms and reduces streptozotocin-induced disturbance of hepatic gene expression in mice. Mol Nutr Food Res 2009, 53(7):859-868.
81. de Boer V.C., Dihal A.A., van der Woude H., Arts I.C., Wolffram S., Alink G.M., et al. Tissue distribution of quercetin in rats and pigs. J Nutr 2005, 135(7):1718-1725.
82. Lunz J.G., Tsuji H., Nozaki I., Murase N., Demetris A.J. An inhibitor of cyclin-dependent kinase, stress-induced p21Waf-1/Cip-1, mediates hepatocyte mito-inhibition during the evolution of cirrhosis. Hepatology 2005, 41(6):1262-1271.
83. Albrecht J.H., Poon R.Y., Ahonen C.L., Rieland B.M., Deng C., Crary G.S. Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver. Oncogene 1998, 16(16):2141-2150.
84. Hershenson M.B. p21Waf1/Cip1 and the prevention of oxidative stress. Am J Physiol Lung Cell Mol Physiol 2004, 286(3):L502-L505.
85. Bellion P., Hofmann T., Pool-Zobel B.L., Will F., Dietrich H., Knaup B., et al. Antioxidant effectiveness of phenolic apple juice extracts and their gut fermentation products in the human colon carcinoma cell line caco-2. J Agric Food Chem 2008, 56(15):6310-6317.
86. Boyer J., Liu R.H. Apple phytochemicals and their health benefits. Nutr J 2004, 3:5.
87. Lee K.W., Kim Y.J., Kim D.O., Lee H.J., Lee C.Y. Major phenolics in apple and their contribution to the total antioxidant capacity. J Agric Food Chem 2003, 51(22):6516-6520.
88. Wojdylo A., Oszmianski J., Laskowski P. Polyphenolic compounds and antioxidant activity of new and old apple varieties. J Agric Food Chem 2008, 56(15):6520-6530.
89. Masumoto S., Akimoto Y., Oike H., Kobori M. Dietary phloridzin reduces blood glucose levels and reverses Sglt1 expression in the small intestine in streptozotocin-induced diabetic mice. J Agric Food Chem 2009, 57(11):4651-4656.
90. Crespy V., Aprikian O., Morand C., Besson C., Manach C., Demigne C., et al. Bioavailability of phloretin and phloridzin in rats. J Nutr 2001, 131(12):3227-3230.
91. Nemeth K., Plumb G.W., Berrin J.G., Juge N., Jacob R., Naim H.Y., et al. Deglycosylation by small intestinal epithelial cell beta-glucosidases is a critical step in the absorption and metabolism of dietary flavonoid glycosides in humans. Eur J Nutr 2003, 42(1):29-42.
92. Kobori M., Masumoto S., Akimoto Y., Oike H. Phloridzin reduces blood glucose levels and alters hepatic gene expression in normal BALB/c mice. Food Chem Toxicol 2012, 50(7):2547-2553.
93. Coskun O., Kanter M., Korkmaz A., Oter S. Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and β-cell damage in rat pancreas. Pharmacol Res 2005, 51(2):117-123.
94. Dias A.S., Porawski M., Alonso M., Marroni N., Collado P.S., Gonzalez-Gallego J. Quercetin decreases oxidative stress, NFκB activation, and iNOS overexpression in liver of streptozotocin-induced diabetic rats. J Nutr 2005, 135(10):2299-2304.
95. Anjaneyulu M., Chopra K. Quercetin an anti-oxidant bioflavonoid, attenuates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 2004, 31(4):244-248.
96. Hao H.H., Lu Q., Tang D.Q., Shao Z.M., Yin X.X., Mou J., et al. Protective effects of quercetin on streptozotocin-induced diabetic nephropathy in rats. Acta Phytother Res 2012, [Epub ahead of print].
97. Wang C., Pan Y., Zhang Q.Y., Wang F.M., Kong L.D. Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation. PLoS One 2012, 7(6):e38285.
98. Liang W., Luo Z., Ge S., Li M., Du J., Yang M., et al. Oral administration of quercetin inhibits bone loss in rat model of diabetic osteopenia. Eur J Pharmacol 2011, 670(1):317-324.
99. Kanter M., Aktas C., Erboga M. Protective effects of quercetin against apoptosis and oxidative stress in streptozotocin-induced diabetic rat testis. Food Chem Toxicol 2012, 50(3-4):719-725.
100. Egert S., Boesch-Saadatmandi C., Wolffram S., Rimbach G., Muller M.J. Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. J Nutr 2010, 140(2):278-284.
101. Larson A.J., Symons J.D., Jalili T. Therapeutic potential of quercetin to decrease blood pressure: review of efficacy and mechanisms. Adv Nutr 2012, 3(1):39-46.
102. Menendez C., Duenas M., Galindo P., Gonzalez-Manzano S., Jimenez R., Moreno L., et al. Vascular deconjugation of quercetin glucuronide: the flavonoid paradox revealed?. Mol Nutr Food Res 2011, 55(12):1780-1790.
103. Galindo P., Rodriguez-Gomez I., Gonzalez-Manzano S., Duenas M., Jimenez R., Menendez C., et al. Glucuronidated quercetin lowers blood pressure in spontaneously hypertensive rats via deconjugation. PLoS One 2012, 7(3):e32673.
104. Kawai Y., Nishikawa T., Shiba Y., Saito S., Murota K., Shibata N., et al. Macrophage as a target of quercetin glucuronides in human atherosclerotic arteries: implication in the anti-atherosclerotic mechanism of dietary flavonoids. J Biol Chem 2008, 283(14):9424-9434.
105. Conseil G., Baubichon-Cortay H., Dayan G., Jault J.M., Barron D., Di Pietro A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci USA 1998, 95(17):9831-9836.
106. Hosokawa N., Hirayoshi K., Kudo H., Takechi H., Aoike A., Kawai K., et al. Inhibition of the activation of heat shock factor in vivo and in vitro by flavonoids. Mol Cell Biol 1992, 12(8):3490-3498.
107. van Meeuwen J.A., Korthagen N., de Jong P.C., Piersma A.H., van Den Berg M. (Anti)estrogenic effects of phytochemicals on human primary mammary fibroblasts, MCF-7 cells and their co-culture. Toxicol Appl Pharmacol 2007, 221(3):372-383.
108. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003 11, 425(6954):191-196.
109. Janssen K., Mensink R.P., Cox F.J., Harryvan J.L., Hovenier R., Hollman P.C., et al. Effects of the flavonoids quercetin and apigenin on hemostasis in healthy volunteers: results from an in vitro and a dietary supplement study. Am J Clin Nutr 1998, 67(2):255-262.
110. Burns J., Yokota T., Ashihara H., Lean M.E., Crozier A. Plant foods and herbal sources of resveratrol. J Agric Food Chem 2002, 50(11):3337-3340.
111. Ribeiro De Lima M.T., Waffo-Teguo P., Teissedre P.L., Pujolas A., Vercauteren J., Cabanis J.C., et al. Determination of stilbenes (trans-astringin, cis- and trans-piceid, and cis- and trans-resveratrol) in Portuguese wines. J Agric Food Chem 1999, 47(7):2666-2670.
112. Zamora-Ros R., Andres-Lacueva C., Lamuela-Raventos R.M., Berenguer T., Jakszyn P., Martinez C., et al. Concentrations of resveratrol and derivatives in foods and estimation of dietary intake in a Spanish population: European prospective investigation into cancer and nutrition (EPIC)-Spain cohort. Br J Nutr 2008, 100(1):188-196.
113. Smoliga J.M., Baur J.A., Hausenblas H.A. Resveratrol and health-a comprehensive review of human clinical trials. Mol Nutr Food Res 2011, 55(8):1129-1141.
114. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444(7117):337-342.
115. Barger J.L., Kayo T., Vann J.M., Arias E.B., Wang J., Hacker T.A., et al. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 2008, 3(6):e2264.
116. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 2006, 127(6):1109-1122.
117. Um J.H., Park S.J., Kang H., Yang S., Foretz M., Mc Burney M.W., et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010, 59(3):554-563.
118. Price N.L., Gomes A.P., Ling A.J., Duarte F.V., Martin-Montalvo A., North B.J., et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 2012, 15(5):675-690.
119. Cho S.J., Jung U.J., Choi M.S. Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice. Br J Nutr 2012, 108(12):2166-2175.
120. Brasnyo P., Molnar G.A., Mohas M., Marko L., Laczy B., Cseh J., et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type-2 diabetic patients. Br J Nutr 2011, 106(3):383-389.
121. Timmers S., Konings E., Bilet L., Houtkooper R.H., van de Weijer T., Goossens G.H., et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011, 14(5):612-622.
122. Poulsen M.M., Vestergaard P.F., Clasen B.F., Radko Y., Christensen L.P., Stodkilde-Jorgensen H., et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013, 62(4):1186-1195.
123. Yoshino J., Conte C., Fontana L., Mittendorfer B., Imai S., Schechtman K.B., et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab 2012, 16(5):658-664.
124. Ejaz A., Wu D., Kwan P., Meydani M. Curcumin inhibits adipogenesis in 3T3-L1 adipocytes and angiogenesis and obesity in C57/BL mice. J Nutr 2009, 139(5):919-925.
125. Weisberg S.P., Leibel R., Tortoriello D.V. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 2008, 149(7):3549-3558.
126. Shao W., Yu Z., Chiang Y., Yang Y., Chai T., Foltz W., et al. Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS One 2012, 7(1):e28784.
127. Shehzad A., Ha T., Subhan F., Lee Y.S. New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases. Eur J Nutr 2011, 50(3):151-161.
128. Mohammadi A., Sahebkar A., Iranshahi M., Amini M., Khojasteh R., Ghayour-Mobarhan M., et al. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Acta Phytother Res 2013, 27(3):374-379.
129. Tsuda T. Regulation of adipocyte function by anthocyanins; possibility of preventing the metabolic syndrome. J Agric Food Chem 2008, 56(3):642-646.
130. Guo H., Xia M., Zou T., Ling W., Zhong R., Zhang W. Cyanidin 3-glucoside attenuates obesity-associated insulin resistance and hepatic steatosis in high-fat diet-fed and db/db mice via the transcription factor FoxO1. J Nutr Biochem 2012, 23(4):349-360.